Provided by Tiger Fintech (Singapore) Pte. Ltd.

Optinose Inc.

9.14
-0.0100-0.11%
Volume:11.59K
Turnover:105.87K
Market Cap:92.06M
PE:-4.31
High:9.17
Open:9.10
Low:9.10
Close:9.15
Loading ...

Company Profile

Company Name:
Optinose Inc.
Exchange:
NASDAQ
Establishment Date:
2000
Employees:
128
Office Location:
1020 Stony Hill Road,Suite 300,Yardley,Pennsylvania,United States
Zip Code:
19067
Fax:
267 395 2119
Introduction:
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Directors

Name
Position
Joseph C. Scodari
Chairman of the Board
Ramy A. Mahmoud
Chief Executive Officer and Director
Catherine Owen
Director
Eric Bednarski
Director
Kyle Dempsey
Director
R. John Fletcher
Director
Sandra L. Helton
Director
Tomas J. Heyman
Director
Wilhelmus Groenhuysen
Director

Shareholders

Name
Position
Ramy A. Mahmoud
Chief Executive Officer and Director
Anthony J. Krick
Vice President and Chief Accounting Officer
Michael F. Marino
Chief Legal Officer and Corporate Secretary
Paul Spence
Chief Commercial Officer